Eli Lilly and Company (LLY)
| Previous close | 584.04 |
| Open | 591.70 |
| Bid | 583.33 x 800 |
| Ask | 584.00 x 1200 |
| Day's range | 581.23 - 586.29 |
| 52-week range | 309.20 - 629.97 |
| Volume | |
| Avg. volume | 3,287,271 |
| Market cap | 552.573B |
| Beta (5Y monthly) | 0.33 |
| PE ratio (TTM) | 104.88 |
| EPS (TTM) | 5.55 |
| Earnings date | 06 Feb 2024 |
| Forward dividend & yield | 4.52 (0.77%) |
| Ex-dividend date | 14 Nov 2023 |
| 1y target est | 630.67 |
Motley Fool1 Monster Dividend Stock Growth Investors Should Load Up On Right Now
Dividend stocks have a well-earned reputation for outperformance. Modern portfolio theory (MPT), however, indicates that growth investors should strictly adhere to a couple of critical guidelines when picking dividend stocks for their portfolios. Among the most important guideposts recommended by the peer-reviewed MPT literature are selecting stocks with dividends lower than the average of the benchmark S&P 500 index; selecting stocks with premium valuations and a track record of positive annual returns; and selecting stocks in fast-growing sectors like healthcare or technology.
Simply Wall St.Is Eli Lilly and Company's (NYSE:LLY) 44% ROE Better Than Average?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
ReutersEli Lilly again extends tender offer to buy Point Biopharma on low participation
Lilly set Dec. 15 as the deadline in a third extension. The Indianapolis-based drugmaker maintained its offer price at $12.50 per share, which is over 10% lower than Point Biopharma's last closing price of $13.80. Lilly had struck a $1.4 billion deal to buy Point Biopharma in October.
